Type 1 Diabetes Mellitus Clinical Trial
— TotCampOfficial title:
Pilot Study: Intensive Education in a Residential Camp Setting for Families of Young Children With Type 1 Diabetes
Verified date | June 2017 |
Source | University of Texas Southwestern Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
18 preschool aged children and their families will attend structured, multidisciplinary, family-centered intensive education sessions over a 3-day weekend in a residential camp setting to address the unique challenges of managing type 1 diabetes mellitus in young children. A second 'booster' session, will be conducted 6 months later.
Status | Completed |
Enrollment | 18 |
Est. completion date | January 2017 |
Est. primary completion date | August 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 34 Months to 68 Months |
Eligibility |
Inclusion Criteria: - Age 3-5.5 years old (+/- 2 months) at the date of first camp session they are eligible to join. - Child and Parents fluent in either English or Spanish. - Type 1 diabetes mellitus diagnosed for at least 10 months previous to date of first camp they are eligible to join. - Taking insulin - Custodial parent or guardian (preferable both parents or guardians) willing to attend both session of camp and the activities scheduled for them. - Parent or guardian must sign consent before any study procedures are performed. Exclusion Criteria: - Neonatal diabetes (diagnosis in the first 3 months of life) or documented MODY; i.e., a likely genetic form of diabetes rather than an autoimmune etiology. - Post-surgical diabetes (e.g., pancreatectomy for congenital hyperinsulinism). Such patients often cannot secrete glucagon, leading to a particularly severe inability to defend against hypoglycemia. - Other severe chronic disease (e.g., cancer, cystic fibrosis) which in the judgment of the investigator is likely to significantly affect glycemic control. - Patients cannot be taking systemic corticosteroids at enrollment because of adverse effects on glycemic control, but we will not disqualify subjects who require such therapy during the study. Inhaled or topical corticosteroids are permissible. - Patients with hypothyroidism or hyperthyroidism must be clinically euthyroid and have free T4 and TSH within age-appropriate reference ranges at last medically indicated testing. Patients with out of range values may be retested after medication dose adjustment. - Developmental delay or behavioral disorder in the patient of sufficient severity, in the judgment of the investigator, to interfere with group activities. - Medical or psychiatric disorder in a parent of sufficient severity, in the judgment of the investigator, to interfere with group activities. - Celiac disease is not an exclusion criterion. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University of Texas Southwestern Medical Center |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Hemoglobin A1c one month pre-camp to one month post-camp Session 1 | As compared to historical controls | One month pre-camp, one month post-camp | |
Primary | Change in Hemoglobin A1c one month pre-camp to one month post-camp Session 2 | As compared to historical controls | One month pre-camp, one month post-camp | |
Secondary | Change in Hypoglycemia frequency one month pre-camp to one month post-camp Session 1 | As measured by continuous glucose monitoring, and quantitated as area under the curve for blood glucoses <70 mg/dL. | One month pre-camp, one month post-camp | |
Secondary | Change in Hypoglycemia frequency one month pre-camp to one month post-camp Session 2 | As measured by continuous glucose monitoring, and quantitated as area under the curve for blood glucoses <70 mg/dL. | One month pre-camp, one month post-camp | |
Secondary | Medical system utilization ( emergency room visits, hospitalizations related to T1DM) | Composite measure. As compared to historical controls. | Duration of participation in study, expected to be 10 months | |
Secondary | Change in PedsQL Family Impact Module one month pre-camp to one month post-camp Session 1 | Parent report | One month pre-camp, one month post-camp | |
Secondary | Change in PedsQL Family Impact Module one month pre-camp to one month post-camp Session 2 | Parent report | One month pre-camp, one month post-camp | |
Secondary | Change in PedsQL Pediatric Quality of Life Inventory one month pre-camp to one month post-camp Session 1 | Parent report for Toddlers, Parent report for Young Children, Young Child Report | One month pre-camp, one month post-camp | |
Secondary | Change in PedsQL Pediatric Quality of Life Inventory one month pre-camp to one month post-camp Session 2 | Parent report for Toddlers, Parent report for Young Children, Young Child Report | One month pre-camp, one month post-camp | |
Secondary | Change in PedsQL Diabetes Module one month pre-camp to one month post-camp Session 1 | Parent report for Toddlers, Parent report for Young Children, Young Child Report | One month pre-camp, one month post-camp | |
Secondary | Change in PedsQL Diabetes Module one month pre-camp to one month post-camp Session 2 | Parent report for Toddlers, Parent report for Young Children, Young Child Report | One month pre-camp, one month post-camp | |
Secondary | Change in Hypoglycemia Fear Survey one month pre-camp to one month post-camp Session 1 | Parents of young children version | One month pre-camp, one month post-camp | |
Secondary | Change in Hypoglycemia Fear Survey one month pre-camp to one month post-camp Session 2 | Parents of young children version | One month pre-camp, one month post-camp | |
Secondary | Change in Behavioral Pediatrics Feeding Assessment one month pre-camp to one month post-camp Session 1 | Behavior section | One month pre-camp, one month post-camp | |
Secondary | Change in Behavioral Pediatrics Feeding Assessment one month pre-camp to one month post-camp Session 2 | Behavior section | One month pre-camp, one month post-camp |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04476472 -
Omnipod Horizon™ Automated Glucose Control System Preschool Cohort
|
N/A | |
Completed |
NCT03635437 -
Evaluation of Safety and Diabetes Status Upon Oral Treatment With GABA in Patients With Longstanding Type-1 Diabetes
|
Phase 1/Phase 2 | |
Completed |
NCT04909580 -
Decision Coaching for Youth and Parents Considering Insulin Delivery Methods for Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT00679042 -
Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol
|
Phase 3 | |
Completed |
NCT03293082 -
Preschool CGM Use and Glucose Variability in Type 1 Diabetes
|
N/A | |
Completed |
NCT04016662 -
Automated Insulin Delivery in Elderly With Type 1 Diabetes (AIDE T1D)
|
Phase 4 | |
Completed |
NCT02527265 -
Afrezza Safety and Pharmacokinetics Study in Pediatric Patients
|
Phase 2 | |
Completed |
NCT03738865 -
G-Pen Compared to Glucagen Hypokit for Severe Hypoglycemia Rescue in Adults With Type 1 Diabetes
|
Phase 3 | |
Completed |
NCT03240432 -
Wireless Innovation for Seniors With Diabetes Mellitus
|
N/A | |
Completed |
NCT03168867 -
Effectiveness Trial of an E-Health Intervention To Support Diabetes Care in Minority Youth (3Ms)
|
N/A | |
Completed |
NCT03674281 -
The VRIF Trial: Hypoglycemia Reduction With Automated-Insulin Delivery System
|
N/A | |
Completed |
NCT03669770 -
Ultrasound Classification and Grading of Lipohypertrophy and Its Impact on Glucose Variability in Type 1 Diabetes
|
||
Recruiting |
NCT03682640 -
Azithromycin Insulin Diet Intervention Trial in Type 1 Diabetes
|
Phase 2 | |
Recruiting |
NCT04096794 -
Chinese Alliance for Type 1 Diabetes Multi-center Collaborative Research
|
||
Completed |
NCT02882737 -
The Impact of Subcutaneous Glucagon Before, During and After Exercise a Study in Patients With Type 1 Diabetes Mellitus
|
N/A | |
Recruiting |
NCT02745808 -
Injectable Collagen Scaffold™ Combined With HUC-MSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
Completed |
NCT02562313 -
A Trial Investigating the Continuous Subcutaneous Insulin Infusion of a Liquid Formulation of BioChaperone Insulin Lispro in Comparison to Humalog®
|
Phase 1 | |
Withdrawn |
NCT02579148 -
Collagen Scaffolds Loaded With HUCMSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
Completed |
NCT02558491 -
Feasibility of a Decision Support System to Reduce Glucose Variability in Subject With T1DM
|
N/A | |
Completed |
NCT02596204 -
Diabetes Care Transformation: Diabetes Data Registry and Intensive Remote Monitoring
|
N/A |